General Information

New Quarterly R&D Tax Credits for cash-strapped SMEs released

April 17th, 2013

From 1 January 2014, the R&D quarterly credits regime will be a new option for small cash-strapped companies wishing to claim under the R&D tax incentive. On Monday, Treasury released its proposed workings of the regime. It will allow companies eligible for the R&D refundable tax offset to obtain the benefit of the offset on a quarterly basis during an income year, rather than waiting until an income tax return is assessed.   Are you eligible for quarterly credits? To qualify for […]

Read More

HURRY! – 18 DAYS UNTIL R&D TAX INCENTIVES DEADLINE

April 11th, 2013

The April 30 R&D Tax Incentive deadline (for June balancing companies) is fast approaching and companies must ensure they register all R&D activities to be eligible for the 43.5% refundable tax offset. The program is open to firms of all sizes in all sectors who are conducting eligible R&D. If your company has an aggregated turnover of less than $20 million per annum you could be entitled to the cash refund of 43.5% of all eligible costs. Click on our eligibility […]

Read More

ZBB Energy receives $180,000 R&D Tax Incentive

April 9th, 2013

ZBB Energy Corporation is an industry leader in the design, development and manufacture of energy storage and power control technology. The company’s Australian subsidiary ZBB Energy Pty has announced an AUS$180,000 R&D Tax Incentive Refund for the 2012 fiscal year.  Eric Apfelbach, CEO and President of ZBB Energy said “We appreciate the continued support of the Australian government for our research activities in Australia. Our R&D efforts on new product designs, cost reduction, and performance improvements on our flow battery […]

Read More

Another win for an Australian Business

April 5th, 2013

Australian Biotechnology Company, Spinifex Pharmaceuticals has announced it has received an R&D Tax Incentive of approximately AUS$1.5 million. The Melbourne company established in June 2005 develops new medicinal drugs for the treatment and management of pain. The funds will be reinvested in further clinical development. Spinifex Pharmaceuticals CEO Tom McCarthy said: “This payment under the R&D tax incentive program is a good example of how Government initiatives can support innovative companies in the biotechnology industry and other sectors”. Click here […]

Read More

Categories

Archives

    Email this job